News
XTNT
0.8300
-0.86%
-0.0072
Weekly Report: what happened at XTNT last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at XTNT last week (0401-0405)?
Weekly Report · 04/08 10:44
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
TipRanks · 04/02 09:11
Xtant Medical’s Earnings at Risk: The Unhedged Perils of Currency Fluctuations
TipRanks · 04/02 06:01
XTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023
Xtant Medical Hldgs reported earnings per share of -3 cents for the fourth quarter of 2023. The company reported revenue of $28.11 million. This was 5.87% better than the analyst estimate of $26.55 million for the quarter.
Investorplace · 04/01 17:53
Xtant Medical files for $150M mixed shelf offering
Xtant Medical Holdings, Inc. Files for $150M mixed shelf offering of up to $150 million. Healthcare Xtant filed a prospectus related to a proposed mixed shelf sale. The company's stock is down 2.7% in the last week.
Seeking Alpha · 04/01 16:47
Xtant Medical Shares Drop 11% Following Wider 4Q Loss
Shares of Xtant Medical down 11% in recent trading. The medical technology company posted a wider loss for the fourth quarter. Revenue rose 84% to $28.1 million. The stock has surged 63% over the past 12 months. The company expects revenue of $116 million in 2024.
Dow Jones · 04/01 15:39
Xtant Medical Holdings (XTNT) Receives a Buy from Craig-Hallum
TipRanks · 04/01 12:36
Xtant Medical Holdings Inc Files For Mixed Shelf Offering Of Up To $150M
Benzinga · 04/01 12:02
XTANT MEDICAL HOLDINGS INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MLN- SEC FILING
Reuters · 04/01 12:00
Xtant Medical GAAP EPS of -$0.03 in-line, revenue of $17.14M misses by $9.41M
Xtant Medical Holdings, Inc. Reports Q4 GAAP EPS of -$0.03 in-line, revenue of $17.14M misses by $9.41M. Establishes Full Year 2024 Revenue Guidance of $112 million - $116 million.
Seeking Alpha · 04/01 11:31
Xtant Medical Q4 GAAP EPS $(0.03) Misses $(0.02) Estimate, Sales $28.11M Beat $26.55M Estimate
Xtant Medical Hldgs reports quarterly losses of $0.03 per share. Missed the analyst consensus estimate of $1 per share by 50 percent. The company reported quarterly sales of $28.11 million which is up 84.7 percent from the same period last year.
Benzinga · 04/01 11:13
*Xtant Medical Holdings Sees FY24 Rev $112M-$116M >XTNT
Dow Jones · 04/01 11:04
XTANT MEDICAL OUTLOOK FY REVENUE USD 112-116 MILLION
Reuters · 04/01 11:00
XTANT MEDICAL ANNOUNCES RECORD FULL YEAR 2023 REVENUE OF $91.3 MILLION
Reuters · 04/01 11:00
*Xtant Medical Holdings 4Q Loss/Shr 3c >XTNT
Dow Jones · 04/01 11:00
Press Release: Xtant Medical Announces Record -3-
Cash used in investing activities includes cash acquired and cash used in financing activities. Cash and cash equivalents and restricted cash at the end of the year totaled $23.7 million. The company has a cash balance of $16.1 million. The Company has a total of $50 million in cash and cash equivalent. The Company expects to use the majority of its cash for investing activities.
Dow Jones · 04/01 11:00
*Xtant Medical Holdings 4Q Rev $28.1M >XTNT
Dow Jones · 04/01 11:00
Press Release: Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 million Establishes Full Year 2024 Revenue Guidance of $112 million - $116 million. Fourth quarter and full year 2023 revenue grew 58% year-over-year to $28.1 million. The company expects full year 2024 revenue to be in the range of $111 million to $120 million.
Dow Jones · 04/01 11:00
*Xtant Medical Holdings 4Q Loss $4.3M >XTNT
Dow Jones · 04/01 11:00
More
Webull provides a variety of real-time XTNT stock news. You can receive the latest news about Xtant Medical through multiple platforms. This information may help you make smarter investment decisions.
About XTNT
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.